Cargando…

Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.

The activation and proliferation of peripheral blood mononuclear cells (PBMNCs) are complex processes involving several surface molecules, cell secretion and response to cytokines. This paper investigates the immunomodulatory effect of prophylactic treatment with interferon alpha 2b (IFN-alpha 2b) u...

Descripción completa

Detalles Bibliográficos
Autores principales: Molto, L., Alvarez-Mon, M., Carballido, J., Manzano, L., Guillen, C., Prieto, A., Olivier, C., Rodriguez-Zapata, M.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033676/
https://www.ncbi.nlm.nih.gov/pubmed/7981084
_version_ 1782136889271123968
author Molto, L.
Alvarez-Mon, M.
Carballido, J.
Manzano, L.
Guillen, C.
Prieto, A.
Olivier, C.
Rodriguez-Zapata, M.
author_facet Molto, L.
Alvarez-Mon, M.
Carballido, J.
Manzano, L.
Guillen, C.
Prieto, A.
Olivier, C.
Rodriguez-Zapata, M.
author_sort Molto, L.
collection PubMed
description The activation and proliferation of peripheral blood mononuclear cells (PBMNCs) are complex processes involving several surface molecules, cell secretion and response to cytokines. This paper investigates the immunomodulatory effect of prophylactic treatment with interferon alpha 2b (IFN-alpha 2b) upon the blastogenic response of PBMNCs from patients with superficial transitional cell carcinoma (STCC) of the bladder to mitogenic signals that interact with surface molecules [phytohaemagglutinin, PHA and anti-CD3 monoclonal antibodies, (MAbs)]. PBMNCs from the patients were studied prior to the transurethral resection (TUR) of the tumour, during the second month of prophylactic intravesical instillation of IFN-alpha 2b and 3 and 6 months after finishing the instillation treatment. The [3H]thymidine uptake of PBMNCs from 17 patients with STCC of the bladder after 5 days of PHA and anti-CD3 MAb stimulus was found to be significantly lower than that of healthy controls (P < 0.05). The addition of interleukin 2 (IL-2) to the culture medium did not correct this defective proliferative response to PHA and the anti-CD3 MAb. There were no significant differences between IL-2 production in PBMNCs from STCC patients after stimulation with PHA and in PBMNCs from healthy controls (P > 0.05). Patients without evidence of recurrence showed a significantly enhanced proliferative response in PBMNC to PHA and anti-CD3 MAb after intravesical prophylactic treatment with interferon-alpha 2b in the follow-up examinations 3 and 6 months after treatment (P < 0.01). However, three patients had evidence of tumour recurrence, and they showed no enhancement of the PBMNC proliferative response to these mitogens in the same examinations. In conclusion, the prophylactic intracavitary treatment of STCC with IFN-alpha 2b may induce a systemic immunomodulatory effect which is associated to the clinical evolution of the disease.
format Text
id pubmed-2033676
institution National Center for Biotechnology Information
language English
publishDate 1994
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20336762009-09-10 Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation. Molto, L. Alvarez-Mon, M. Carballido, J. Manzano, L. Guillen, C. Prieto, A. Olivier, C. Rodriguez-Zapata, M. Br J Cancer Research Article The activation and proliferation of peripheral blood mononuclear cells (PBMNCs) are complex processes involving several surface molecules, cell secretion and response to cytokines. This paper investigates the immunomodulatory effect of prophylactic treatment with interferon alpha 2b (IFN-alpha 2b) upon the blastogenic response of PBMNCs from patients with superficial transitional cell carcinoma (STCC) of the bladder to mitogenic signals that interact with surface molecules [phytohaemagglutinin, PHA and anti-CD3 monoclonal antibodies, (MAbs)]. PBMNCs from the patients were studied prior to the transurethral resection (TUR) of the tumour, during the second month of prophylactic intravesical instillation of IFN-alpha 2b and 3 and 6 months after finishing the instillation treatment. The [3H]thymidine uptake of PBMNCs from 17 patients with STCC of the bladder after 5 days of PHA and anti-CD3 MAb stimulus was found to be significantly lower than that of healthy controls (P < 0.05). The addition of interleukin 2 (IL-2) to the culture medium did not correct this defective proliferative response to PHA and the anti-CD3 MAb. There were no significant differences between IL-2 production in PBMNCs from STCC patients after stimulation with PHA and in PBMNCs from healthy controls (P > 0.05). Patients without evidence of recurrence showed a significantly enhanced proliferative response in PBMNC to PHA and anti-CD3 MAb after intravesical prophylactic treatment with interferon-alpha 2b in the follow-up examinations 3 and 6 months after treatment (P < 0.01). However, three patients had evidence of tumour recurrence, and they showed no enhancement of the PBMNC proliferative response to these mitogens in the same examinations. In conclusion, the prophylactic intracavitary treatment of STCC with IFN-alpha 2b may induce a systemic immunomodulatory effect which is associated to the clinical evolution of the disease. Nature Publishing Group 1994-12 /pmc/articles/PMC2033676/ /pubmed/7981084 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Molto, L.
Alvarez-Mon, M.
Carballido, J.
Manzano, L.
Guillen, C.
Prieto, A.
Olivier, C.
Rodriguez-Zapata, M.
Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.
title Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.
title_full Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.
title_fullStr Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.
title_full_unstemmed Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.
title_short Intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic T-cell activation.
title_sort intracavitary prophylactic treatment with interferon alpha 2b of patients with superficial bladder cancer is associated with a systemic t-cell activation.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033676/
https://www.ncbi.nlm.nih.gov/pubmed/7981084
work_keys_str_mv AT moltol intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation
AT alvarezmonm intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation
AT carballidoj intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation
AT manzanol intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation
AT guillenc intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation
AT prietoa intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation
AT olivierc intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation
AT rodriguezzapatam intracavitaryprophylactictreatmentwithinterferonalpha2bofpatientswithsuperficialbladdercancerisassociatedwithasystemictcellactivation